In addition to his experience at Roche, Braun has also held roles at an artificial intelligence (AI)-driven life sciences start-up and as strategy consultant to emerging healthcare companies
Nordic Nanovector has announced the appointment of Peter L Braun as CEO. He will take up the position on 6 April 2021 and will be based in the company's office in Zug, Switzerland.
Braun has extensive commercialisation experience with oncology products and knowledge of pharmaceutical markets worldwide from a career spanning nearly 30 years at Hoffmann-La-Roche.
During his career at Roche, Braun led the Lifecycle Management teams for the targeted cancer therapies Herceptin (trastuzumab) and Tarceva (erlotinib).
He has also held various operational leadership positions including being country general manager and multiple commercial roles in Europe, US and Latin America. He has developed expertise across multiple strategic and operational roles including development, manufacturing, business development and market access for therapeutic products in several geographies and other therapeutic areas, including rare diseases and infectious diseases.
Jan H. Egberts, Chairman of Nordic Nanovector's Board of Directors, said: "I am delighted that Peter has agreed to join us at this important time for Nordic Nanovector. Our aim was to leverage on our important recent progress by recruiting a strong commercial CEO who can refine and drive the company's plans towards the regulatory filing and commercialisation of Betalutin. We are confident that, with Peter's track record in and enthusiasm for the development and commercialisation of innovative targeted oncology products, we can build on the top-line data from the PARADIGME trial expected later in the year by clearly defining our plans for Betalutin's commercialisation. These are key steps on our path to becoming a leader in targeted radiopharmaceuticals."
"I would like to take this opportunity to thank Lars Nieba for his leadership of the company during the last 12 months as Interim CEO. His dedication and efforts have contributed to the considerable progress Nordic Nanovector has made in this time."